KRN 101 was being investigated for its first indication, cancer-related distress. However, before it could be tested in humans, preclinical toxicology studies were necessary to evaluate the safety of the proprietary mycelium-based API. Preclinical toxicology studies involved testing the drug’s toxicity, pharmacokinetics (how the drug was absorbed, distributed, metabolised, and excreted by the body), and potential for adverse effects on rats. These studies were designed to identify any potential safety concerns that may arise during the pharmacokinetics trials in humans.

Therapeutic ready-made meals are made by selecting appropriate ingredients for specific health conditions, like cancer or diabetes, and cooking them in their packaging using the Micvac process. This method preserves their freshness and nutritional value while also reducing food waste and providing a long shelf life of up to 60 days. These convenient and nutritious meals can help manage and prevent health issues while being environmentally sustainable.

Successful execution of drug discovery and technology transfer of production process for KRN 101. KRN-101 is an investigational mycelium-based drug product extracted from Albert Labs’ patented process. The lab employed their expertise in microbiology and analytical characterization, validation, including purification and formulation development, to produce the mycelium extract and formulate it into a standardized pharma-grade product. Additionally, stability testing was performed to ensure product efficacy during storage. The lab’s successful execution of these processes demonstrates its ability to develop and produce high-quality pharmaceutical products.

Cannabis Science was collaborating with Dana-Farber Cancer Institute at Harvard to investigate the potential of using cannabinoids in combination with radiotherapy and immunotherapy to treat different types of cancer. Prados Labs’ preclinical studies, which include drug discovery, animal toxicology, and in vitro and in vivo experiments, aim to validate the efficacy and safety of cannabinoid-based therapies for cancer, with a focus on developing treatments for drug-resistant or intolerant patients.

Prados Labs provides various drug discovery and preclinical research services to INgenu CRO clients, including expertise in target identification and validation, hit identification and lead optimization, ADMET studies, chemical synthesis and scale-up, in vitro and in vivo studies, pharmacokinetic and pharmacodynamic studies, and safety and toxicology studies. This partnership would allow INgenu CRO to offer a wider range of resources and expertise to their clients, which would improve the drug development process and increase the likelihood of success in clinical development.